Stemline Therapeutics

Stemline Therapeutics

Stemline Therapeutics, Inc.. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
AUD1.0b (Public information from May 2020)
New York City New York (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR20152016201720182019
R&D budget26.0m25.0m41.0m41.0m45.0m

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

$50.0k

Seed

$12.5m

Series A

$12.5m

Series A
N/A

$1.3m

Debt
N/A

$600k

Debt
N/A

$740k

Debt
N/A

N/A

IPO
N/A

$92.0m

Post IPO Equity
*
N/A

$88.0m

Post IPO Equity
*

$677m

Valuation: $677m

Acquisition
Total FundingAUD38.7m

Recent News about Stemline Therapeutics

Edit
More about Stemline Therapeuticsinfo icon
Edit

Stemline Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and delivering transformative therapies for oncology patients. The company focuses on creating a broad pipeline of innovative treatments aimed at improving the lives of individuals battling cancer. Stemline serves patients, healthcare providers, and the broader medical community, operating primarily in the oncology market. The business model revolves around extensive research and development, clinical trials, and the commercialization of its proprietary therapies. Revenue is generated through the sale of these therapies, partnerships, and licensing agreements. Stemline leverages its scientific leadership and commercial expertise to bring cutting-edge treatments to market, addressing unmet medical needs in cancer care.

Keywords: biopharmaceutical, oncology, cancer, innovative therapies, clinical trials, scientific leadership, commercial expertise, transformative treatments, healthcare, research and development.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.